Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 124249 in mild to moderate inverse psoriasis
NCT02695940Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of delgocitinib in inverse psoriasis, sponsored by LEO Pharma. Started Mar 2016; status: completed.
02
Drugs
delgocitinib
03
Conditions
inverse psoriasis
Beyond the preview
Go deeper on NCT02695940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695940.